Vireo Growth (VREOF) Cash from Operations (2020 - 2026)
Vireo Growth (VREOF) posted Cash from Operations of 11900000.0 for Q1 2026, down 36.21% sequentially from 18655743.0 in Q4 2025, and up 450.0% YoY from 2163636.36 in Q1 2025.
Vireo Growth (VREOF) Cash from Operations (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cash from Operations for 7 years, with the latest figure at 11900000.0 in Q1 2026.
- Quarterly Cash from Operations rose 450.0% year-over-year to 11900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19011491.0 (up 252.77% YoY) and the FY2025 annual result came in at 3711491.0, up 136.26% from the prior year.
- Cash from Operations fell to 11900000.0 in Q1 2026 per VREOF's latest filing, from 18655743.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 18655743.0 in Q4 2025 and troughed at 6792823.0 in Q3 2025.
- A 5-year average of 803660.59 and a median of 2591374.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations slumped 49694.9% in 2025, then surged 450.0% in 2026.
- Over 5 years, Cash from Operations stood at 6119043.0 in 2022, then jumped by 92.49% to 459544.0 in 2023, then plunged by 1302.11% to 6443302.0 in 2024, then surged by 389.54% to 18655743.0 in 2025, then plunged by 36.21% to 11900000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 11900000.0, 18655743.0, and 6792823.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | 2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.90 Mn |
| Mar 31, 2026 | 11.90 Mn |
| Dec 31, 2025 | 18.66 Mn |
| Dec 31, 2025 | 18.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -4.75 Mn |
| Jun 30, 2025 | -4.75 Mn |
| Mar 31, 2025 | -3.40 Mn |
| Mar 31, 2025 | -3.40 Mn |
| Dec 31, 2024 | -6.44 Mn |
| Dec 31, 2024 | -6.44 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | -9,542.00 |
| Jun 30, 2024 | -9,542.00 |
| Mar 31, 2024 | -1.19 Mn |
| Mar 31, 2024 | -1.19 Mn |
| Dec 31, 2023 | -459,544.00 |
| Dec 31, 2023 | -459,544.00 |